At CymaBay, we are committed to improving the lives of patients with liver and other chronic diseases by developing and providing access to innovative therapies.
We are dedicated to enhancing the quality of healthcare by addressing the complex needs of patients, caregivers and communities and advancing medical knowledge.
CymaBay Therapeutics to Present at Three Investor Conferences Mon, 13 Nov 2017 13:00:00 +0000 NEWARK, Calif., Nov. 13, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates Wed, 08 Nov 2017 21:01:00 +0000 NEWARK, Calif., Nov. 08, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
CymaBay Therapeutics, Inc. to Host Earnings Call Wed, 08 Nov 2017 18:00:00 +0000 NEW YORK, NY / ACCESSWIRE / November 8, 2017 / CymaBay Therapeutics, Inc. (NASDAQ: CBAY ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 PM Eastern ...
CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8 Wed, 01 Nov 2017 12:30:00 +0000 NEWARK, Calif., Nov. 01, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
CymaBay Therapeutics to Present at Two Investor Conferences Mon, 18 Sep 2017 12:00:00 +0000 NEWARK, Calif., Sept. 18, 2017-- CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, ...
Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning Tue, 12 Sep 2017 16:50:03 +0000 The drug warning that sent ICPT stock down on Tuesday came in the form of a letter sent to physicians. In the letter concerning Ocaliva, Intercept Pharmaceuticals Inc notes that there have been connections between overdosing on the drug and certain liver issues. “Today’s letter/disclosure, in our view, will likely add another layer of caution as physicians may find Ocaliva dosing more cumbersome and patients more reluctant to initiate therapy,” Joseph Schwartz, a Leerink analyst, said in a statement obtained by Investor’s Business Daily.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.